Galectin Therapeutics Inc. Stock Earnings Report NASDAQ:GALT
Current P/E ratio: 0 | Price (Nov 25, 2022, EOD): $1.29 (Find current average P/E ratios for all sectors below)
GALT Upcoming Earnings
Currently no data available.GALT Analysts Price Targets
Currently no data available.About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Last 3 Quarters for GALT Premium
Below you can see how GALT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Average Sector P/E ratio
Is your stock priced above or below the average P/E ratio?
A higher P/E ratio shows that investors are willing to pay a higher share price today because of growth expectations in the future. For example, a company with a current P/E of 25, trades at 25 times today's earnings.
| Name | Number of firms | Average PE |
|---|---|---|
| Advertising | 47 | 20 |
| Aerospace/Defense | 77 | 35 |
| Air Transport | 18 | 15 |
| Apparel | 51 | 26 |
| Auto & Truck | 13 | 15 |
| Auto Parts | 46 | 16 |
| Bank (Money Center) | 7 | 11 |
| Banks (Regional) | 611 | 17 |
| Beverage (Alcoholic) | 21 | 38 |
| Beverage (Soft) | 34 | 35 |
| Broadcasting | 27 | 14 |
| Brokerage & Investment Banking | 39 | 14 |
| Building Materials | 42 | 23 |
| Business & Consumer Services | 165 | 32 |
| Cable TV | 14 | 156 |
| Chemical (Basic) | 43 | 14 |
| Chemical (Diversified) | 6 | 10 |
| Chemical (Specialty) | 94 | 25 |
| Coal & Related Energy | 22 | 7 |
| Computer Services | 106 | 27 |
| Computers/Peripherals | 48 | 24 |
| Construction Supplies | 44 | 22 |
| Diversified | 23 | 45 |
| Drugs (Biotechnology) | 503 | 77 |
| Drugs (Pharmaceutical) | 267 | 22 |
| Education | 35 | 21 |
| Electrical Equipment | 113 | 28 |
| Electronics (Consumer & Office) | 20 | 18 |
| Electronics (General) | 153 | 49 |
| Engineering/Construction | 54 | 24 |
| Entertainment | 107 | 150 |
| Environmental & Waste Services | 82 | 70 |
| Farming/Agriculture | 31 | 63 |
| Financial Svcs. (Non-bank & Insurance) | 232 | 36 |
| Food Processing | 88 | 55 |
| Food Wholesalers | 17 | 43 |
| Furn/Home Furnishings | 35 | 17 |
| Green & Renewable Energy | 22 | 88 |
| Healthcare Products | 242 | 160 |
| Healthcare Support Services | 128 | 131 |
| Heathcare Information and Technology | 129 | 132 |
| Homebuilding | 32 | 64 |
| Hospitals/Healthcare Facilities | 36 | 145 |
| Hotel/Gaming | 65 | 171 |
| Household Products | 127 | 26 |
| Information Services | 69 | 283 |
| Insurance (General) | 19 | 693 |
| Insurance (Life) | 24 | 15 |
| Insurance (Prop/Cas.) | 51 | 71 |
| Investments & Asset Management | 192 | 120 |
| Machinery | 120 | 27 |
| Metals & Mining | 92 | 37 |
| Office Equipment & Services | 22 | 16 |
| Oil/Gas (Integrated) | 4 | 13 |
| Oil/Gas (Production and Exploration) | 269 | 19 |
| Oil/Gas Distribution | 24 | 606 |
| Oilfield Svcs/Equip. | 136 | 28 |
| Packaging & Container | 24 | 43 |
| Paper/Forest Products | 15 | 20 |
| Power | 52 | 28 |
| Precious Metals | 83 | 98 |
| Publishing & Newspapers | 31 | 28 |
| R.E.I.T. | 234 | 91 |
| Real Estate (Development) | 20 | 146 |
| Real Estate (General/Diversified) | 12 | 31 |
| Real Estate (Operations & Services) | 57 | 23 |
| Recreation | 63 | 50 |
| Reinsurance | 2 | 153 |
| Restaurant/Dining | 77 | 66 |
| Retail (Automotive) | 26 | 20 |
| Retail (Building Supply) | 17 | 202 |
| Retail (Distributors) | 80 | 28 |
| Retail (General) | 18 | 22 |
| Retail (Grocery and Food) | 13 | 38 |
| Retail (Online) | 70 | 319 |
| Retail (Special Lines) | 89 | 25 |
| Rubber& Tires | 4 | 15 |
| Semiconductor | 72 | 109 |
| Semiconductor Equip | 39 | 26 |
| Shipbuilding & Marine | 10 | 30 |
| Shoe | 11 | 27 |
| Software (Entertainment) | 86 | 60 |
| Software (Internet) | 30 | 90 |
| Software (System & Application) | 363 | 144 |
| Steel | 32 | 11 |
| Telecom (Wireless) | 18 | 27 |
| Telecom. Equipment | 91 | 66 |
| Telecom. Services | 67 | 115 |
| Tobacco | 17 | 33 |
| Transportation | 18 | 24 |
| Transportation (Railroads) | 8 | 20 |
| Trucking | 33 | 18 |
| Utility (General) | 16 | 26 |
| Utility (Water) | 17 | 46 |
| Total Market | 7053 | 61 |
| Total Market (without financials) | 5878 | 62 |
Updated: Jan 2020
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatiti... GALT Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
